Talquetamab + Cyp Substrates Interaction
Majorinteraction on record
Description
Talquetamab causes cytokine release that may suppress CYP enzyme activity, resulting in increased exposure of CYP substrates. Risk is highest during step-up dosing (up to 14 days after first dose) and during/after cytokine release syndrome.
Mechanism
Cytokine-mediated suppression of CYP enzyme activity
Source: NLP:talquetamab